New hope for kidney transplant rejection: tocilizumab added to standard therapy

NCT ID NCT07006532

Recruiting now Disease control Sponsor: Shahid Beheshti University of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the drug tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) can better treat chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants will be enrolled to see if the combination improves kidney function and reduces harmful antibodies. The goal is to find a more effective way to save transplanted kidneys from failing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tocilizumab
What this could lead to: If successful, this could offer a more effective treatment for chronic kidney transplant rejection, potentially improving long-term graft survival.
What could go wrong: This is a small, early-phase trial with only 50 participants. The added benefit of tocilizumab is uncertain, and there are risks of infection and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT REJECTION

Contacts and locations

Locations

Nooshin Dalili
RECRUITING

Tehran, 1666663421, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.